Department of Surgery, Breast Center, Dalian Central Hospital of Dalian Medical University, Dalian, China.
J Breast Cancer. 2014 Sep;17(3):250-5. doi: 10.4048/jbc.2014.17.3.250. Epub 2014 Sep 30.
Near-infrared fluorescence imaging with indocyanine green (ICG) has the potential to improve sentinel lymph node (SLN) mapping in breast cancer. In this clinical trial, we compared the potential value of ICG combined with blue dye with that of blue dye alone for detecting SLNs.
Patients undergoing SLN biopsy (SLNB) between November 2010 and November 2013 were included. Up to December 2011, SLNs were detected by using patent blue (PB) alone, and since January 2012, by using PB in combination with ICG. The patients were divided into the following two groups: group A (ICG-PB; n=96) and group B (PB; n=73), and SLN detection parameters were compared between the groups. All patients underwent level I and II axillary dissections after SLNB.
In group A, the SLN detection rate was 96.9% (93/96), the accuracy of detection was 98.9% (92/93), and the false-negative rate (FNR) was 3.4% (1/29). In group B, the SLN detection rate was 84.9% (62/73), the accuracy of detection was 96.8% (60/62), and the FNR was 11.1% (2/18). The ICG-PB group showed significantly superior results compared to the PB group for SLN detection (p=0.005) and a greatly improved FNR.
The combined fluorescence and blue dye-based tracer technique was superior to the use of blue dye alone for identifying SLNs, and for predicting axillary lymph node status in patients with breast cancer; in addition, the combined technique had reduced false-negative results.
吲哚菁绿（ICG）近红外荧光成像有可能改善乳腺癌前哨淋巴结（SLN）的定位。在这项临床试验中，我们比较了 ICG 联合蓝染剂与单独使用蓝染剂检测 SLN 的潜在价值。
纳入 2010 年 11 月至 2013 年 11 月期间接受 SLN 活检（SLNB）的患者。截至 2011 年 12 月，仅使用专利蓝（PB）检测 SLN，自 2012 年 1 月起，使用 PB 联合 ICG 检测。将患者分为以下两组：A 组（ICG-PB；n=96）和 B 组（PB；n=73），比较两组间 SLN 检测参数。所有患者在 SLNB 后均接受 I、II 水平腋窝清扫术。
A 组 SLN 检出率为 96.9%（93/96），检出准确率为 98.9%（92/93），假阴性率（FNR）为 3.4%（1/29）。B 组 SLN 检出率为 84.9%（62/73），检出准确率为 96.8%（60/62），FNR 为 11.1%（2/18）。与 PB 组相比，ICG-PB 组在 SLN 检测（p=0.005）和降低 FNR 方面具有显著优势。
荧光联合蓝染剂示踪技术优于单独使用蓝染剂，可用于识别 SLN，预测乳腺癌患者腋窝淋巴结状态，并且降低了假阴性结果。
